Riskpilot← Back to searchSign inGet full accessBergentoft Pharma Consulting AB
ABActiveOrg 5590167523Artillerigatan 40 A Lgh 1302Business and other management consultancy activities · NACE 7020Est. 20151-4 employees
Revenue 2025
SEK 0
EBITDA margin
—
-105% vs 2024
Equity ratio
67.1%
Financial strength
Net profit 2025
SEK -24K
+51% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -333K | -105% |
| Net profit | SEK -24K | +51% |
| Total assets | SEK 2,6M | -19% |
| Equity | SEK 1,7M | -12% |
| Employees | — | — |
Legal name
Bergentoft Pharma Consulting AB
Org number
5590167523
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
9 juni 2015
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Företaget bedriver konsultverksamhet inom pharma sektorn i Norden rörande följande områden: Marknadsföring Market Access Försäljning Clinical operations Management konsultjänster
Address
Artillerigatan 40 A Lgh 1302
Email
peter.bergentoft@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 176 | 2 054 | 1 984 | 6 | 0 |
| Staff expenses | — | −734 | −197 | −105 | −282 |
| EBITDA | 811 | 1 266 | 1 718 | −162 | −333 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 811 | 1 266 | 1 718 | −162 | −333 |
| Net financials | — | 0 | 16 | 83 | 39 |
| Profit before tax | 762 | 966 | 1 299 | −49 | −24 |
| Tax | −160 | −199 | −272 | — | — |
| Net profit | 602 | 766 | 1 027 | −49 | −24 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 699 | 2 938 | 3 979 | 3 174 | 2 581 |
| Equity | 890 | 1 471 | 2 218 | 1 964 | 1 731 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 409 | 766 | 626 | 105 | 15 |
| Total debt | 409 | 766 | 626 | 105 | 15 |
EBITDA margin
-33284200.0%
This company
15.8%
Market median
-210659594% vs market
20212025
Equity ratio
67.1%
This company
38.2%
Market median
+76% vs market
20212025
Return on equity
-1.4%
This company
18.4%
Market median
-108% vs market
20212025
Net profit margin
-2420000.0%
This company
8.1%
Market median
-29876643% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RA Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bergentoft Pharma Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ragnhild Anna Maria Bergentoft | Deputy Chief Executive Officer | 0 companies |
| Jakob Karl Vilhelm Bergentoft | Deputy Board Member | 0 companies |
| Oskar Erik Bergentoft | Deputy Board Member | 0 companies |
| Peter Erik Bergentoft | Chairman | 0 companies |